Drug-induced angioedema without urticaria - Incidence, prevention and management

被引:122
|
作者
Agostoni, A [1 ]
Cicardi, M [1 ]
机构
[1] Univ Milan, IRCCS Maggiore Hosp, Dept Internal Med, I-20122 Milan, Italy
关键词
D O I
10.2165/00002018-200124080-00004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Angioedema without urticaria is a clinical syndrome characterised by self-limiting local swellings involving the deeper cutaneous and mucosa tissue layers. Most occurrences of angioedema respond to treatment with a histamine H-1 receptor blocker (antihistamine) because they are an allergic or parallergic reaction. A small number of cases do not respond to antihistamine treatment. Such cases tend to occur in patients with deficiency or dysfunction of the inhibitor of the first component of the complement (Cl-INH), but more rarely can occur in patients with other conditions and as an adverse drug reaction. Angioedema is well documented in patients taking ACE inhibitors. Considering that 35 to 40 million patients are treated worldwide with ACE inhibitors, this drug class could account for several hundred deaths per year from laryngeal oedema. ACE inhibitors certainly do not mediate angioedema through an allergic or idiosyncratic reaction. For this reason the relationship with this drug is often missed and consequently quite underestimated. Rare instances of angioedema have also been reported with angiotensin II receptor antagonists. This adverse effect seems to occur less frequently with angiotensin II receptor antagonists than with ACE inhibitors. However, we do not know whether this adverse effect has the same mechanism with the 2 classes of medications. Some cases of severe angioedema have been recently reported after treatment with fibrinolytic agents. Scattered reports suggest the possibility of angioedema associated with the use of estrogens, antihypertensive drugs other than ACE inhibitors, and psychotropic drugs. Angioedema can also occur with nonsteroidal anti-inflammatory drugs. Prevention of angioedema relies first on the patient history. Estrogen and ACE inhibitors should be avoided in a patient with congenital or acquired Cl-INH deficiency. In the case of ACE inhibitors, the appearance of angioedema following long term treatment does not lessen the probability that such an agent could be the cause. The most important action to take in a patient with suspected drug-induced angioedema is to discontinue the pharmacological agent. Epinephrine (adrenaline), diphenydramine and intravenous methylprednisolone have been proposed for the medical management of airway obstruction, but so far no controlled studies have demonstrated their efficacy. If the acute airway obstruction leads to life-threatening respiratory compromise an emergency cricothyroidotomy must be performed.
引用
收藏
页码:599 / 606
页数:8
相关论文
共 50 条
  • [1] Drug-Induced Angioedema without UrticariaIncidence, Prevention and Management
    Angelo Agostoni
    Marco Cicardi
    Drug Safety, 2001, 24 : 599 - 606
  • [2] Prevention of nonsteroidal inflammatory drug-induced urticaria and/or angioedema
    Nosbaum, Audrey
    Braire-Bourrel, Marion
    Dubost, Rolande
    Faudel, Amelie
    Parat, Stephanie
    Nicolas, Jean-Francois
    Berard, Frederic
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 110 (04) : 263 - 266
  • [3] Drug-Induced Angioedema Without Urticaria: A Case Report
    Raikar, Shrinivas R.
    Sreeraj, G.
    Sneha, Sneha
    Janarthanan, R.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [4] Drug-induced angioedema without urticaria: prevalence and clinical features
    Leeyaphan, C.
    Kulthanan, K.
    Jongjareamprasert, K.
    Dhana, N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (06) : 685 - 691
  • [5] Drug-induced urticaria and angioedema in Latin America
    Jares, E. J.
    Sanchez Borges, M.
    Ensina, L. F.
    Arias Cruz, A.
    Gomez, M.
    Diez-Zuluaga, S.
    Ramirez-Giraldo, B. H.
    Gonzalez Diaz, S.
    Mimessi, G.
    Macias Weinmann, A.
    Sole, D.
    Serrano, C.
    Camelo Nunes, I
    De Falco, A.
    Barayazarra, S.
    Cherrez, I
    Schuhl, J.
    Salvatierra, A.
    Cuello, M. N.
    Toche Pinaud, P.
    Mercovich, G.
    Vinuessa, M.
    Weisz, A.
    Zanacchi, A.
    Andrade, D.
    Machado, L.
    Cardona Villa, R.
    ALLERGY, 2013, 68 : 387 - 388
  • [6] Drug-induced delirium - Incidence, management and prevention
    Carter, GL
    Dawson, AH
    Lopert, R
    DRUG SAFETY, 1996, 15 (04) : 291 - 301
  • [7] Drug-Induced Pancreatitis Incidence, Management and Prevention
    Balani, Anil R.
    Grendell, James H.
    DRUG SAFETY, 2008, 31 (10) : 823 - 837
  • [8] DRUG-INDUCED DEMENTIA - INCIDENCE, MANAGEMENT AND PREVENTION
    STARR, JM
    WHALLEY, LJ
    DRUG SAFETY, 1994, 11 (05) : 310 - 317
  • [9] Drug-induced urinary retention - Incidence, management and prevention
    Verhamme, Katia M. C.
    Sturkenboom, Miriam C. J. M.
    Stricker, Bruno H. Ch
    Bosch, Ruud
    DRUG SAFETY, 2008, 31 (05) : 373 - 388
  • [10] Drug-Induced Oesophageal DisordersPathogenesis, Incidence, Prevention and Management
    Daniel Jaspersen
    Drug Safety, 2000, 22 : 237 - 249